Biotech in Russia: Money and a New trial for Hepatitis

22/03/2016 - 2 minutes

The Biotech MYR Pharma (Germany) is launching German-Russian phase IIb trials for chronic hepatitis B & D infections in partnership with Moscow’s Hepatera (Russia).

myr_hepatera_hepatitis_russian_biotech_myrcludex_rvc_maxwellMYR was founded in 2010 and is based in Burgwedel, Germany, supported by investors Maxwell Biotech and High-Tech Gründerfonds (HTGF).

Hepatera, on the other hand, is actually the first Russian biotech we’ve encountered – which is perhaps an early indication of the emerging market growing in Moscow.

For example, investors of Hepatera also include Maxwell Biotech Venture Fund (MBVF). This is the first Russian venture fund fully dedicated to investments in the life sciences sector, created with the participation of the Russian Government‘s Russian Venture Company (RVC).

Hepatera’s focus is the development of safe and effective drugs for the treatment of liver diseases for the Russian market, and this includes Myrcludex B in partnership with MYR.

Myrcludex B is a first-in-class entry inhibitor for treatment of chronic Hepatitis B (HBV) and Hep-D (HDV) viral infections,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!